CSIMarket
 


Alaunos Therapeutics Inc   (TCRT)
Other Ticker:  
 
 

TCRT's Net Cash Flow Growth by Quarter and Year

Alaunos Therapeutics Inc 's Net Cash Flow results by quarter and year




TCRT Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 1.25 -15.67 -18.05
III Quarter September -6.37 -8.27 14.98 -17.48
II Quarter June -19.12 -8.24 -23.31 91.26
I Quarter March -15.56 -7.80 -15.01 0.00
FY   -41.05 -23.06 -39.01 55.73



TCRT Net Cash Flow third quarter 2023 Y/Y Growth Comment
Alaunos Therapeutics Inc in the third quarter 2023 recorded net cash outflow of $ -6.37 millions.

According to the results reported in the third quarter 2023, Alaunos Therapeutics Inc achieved the best Net Cash Flow growth in Major Pharmaceutical Preparations industry. While Alaunos Therapeutics Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the third quarter 2023.




TCRT Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Alaunos Therapeutics Inc 's third quarter 2023 Net Cash Flow $ -6.37 millions TCRT's Income Statement
Alaunos Therapeutics Inc 's third quarter 2022 Net Cash Flow $ -8.27 millions Quarterly TCRT's Income Statement
New: More TCRT's historic Net Cash Flow Growth >>


TCRT Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Alaunos Therapeutics Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TCRT's III. Quarter Q/Q Net Cash Flow Comment
Although Alaunos Therapeutics Inc in the III. Quarter 2023 admitted net cash outflow of $ -6.37 millions, management mentioned, that current results point to improvement relative to the -19.12 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Alaunos Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Alaunos Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TCRT's III. Quarter Q/Q Net Cash Flow Comment
Although Alaunos Therapeutics Inc in the III. Quarter 2023 revealed net cash outflow of $ -6.37 millions, it should be said, that current results point to improvement in contrast to the -19.12 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Alaunos Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Alaunos Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Alaunos Therapeutics Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ -39.80 $ -41.69 $ -30.82 $ -23.06 $ -39.98
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment


Alaunos Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment


Alaunos Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
TCRT's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for TCRT's Competitors
Net Cash Flow Growth for Alaunos Therapeutics Inc 's Suppliers
Net Cash Flow Growth for TCRT's Customers

You may also want to know
TCRT's Annual Growth Rates TCRT's Profitability Ratios TCRT's Asset Turnover Ratio TCRT's Dividend Growth
TCRT's Roe TCRT's Valuation Ratios TCRT's Financial Strength Ratios TCRT's Dividend Payout Ratio
TCRT's Roa TCRT's Inventory Turnover Ratio TCRT's Growth Rates TCRT's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Nascent Biotech Inc-4.04%$ -4.038 millions
Halozyme Therapeutics Inc -5.63%$ -5.629 millions
Vystar Corporation-6.05%$ -6.052 millions
Ideaya Biosciences Inc -7.27%$ -7.268 millions
Phibro Animal Health Corporation-7.87%$ -7.874 millions
Luna Innovations Inc-9.06%$ -9.058 millions
Puma Biotechnology Inc -13.53%$ -13.534 millions
Fulgent Genetics Inc -14.21%$ -14.211 millions
Prestige Consumer Healthcare Inc -16.52%$ -16.522 millions
Omniab Inc -20.57%$ -20.566 millions
Gossamer Bio Inc -22.91%$ -22.914 millions
Alnylam Pharmaceuticals Inc -24.60%$ -24.599 millions
Emmaus Life Sciences Inc -26.90%$ -26.904 millions
Kala Bio inc -27.38%$ -27.384 millions
Protara Therapeutics Inc -29.54%$ -29.540 millions
Msa Safety Incorporated-31.72%$ -31.716 millions
Avalo Therapeutics inc -32.14%$ -32.143 millions
Biovie Inc -32.27%$ -32.265 millions
Veracyte inc -32.97%$ -32.966 millions
Coherus Biosciences inc -35.07%$ -35.068 millions
Biomarin Pharmaceutical Inc-35.76%$ -35.762 millions
International Stem Cell Corporation-40.00%$ -40.000 millions
Arvinas Inc -42.82%$ -42.822 millions
89bio Inc -44.85%$ -44.846 millions
Assertio Holdings inc -46.56%$ -46.561 millions
Infusystem Holdings Inc -48.08%$ -48.077 millions
Eqrx Inc -48.96%$ -48.965 millions
Privia Health Group Inc -49.62%$ -49.617 millions
Nektar Therapeutics-49.69%$ -49.693 millions
Avinger Inc -53.79%$ -53.788 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com